Mutation Analysis Links Angioimmunoblastic T-Cell Lymphoma to Clonal Hematopoiesis
|
By LabMedica International staff writers Posted on 13 Oct 2021 |

Image: Bone marrow aspirate from a patient with peripheral T-cell lymphoma (Photo courtesy of Peter Maslak, MD)
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphoid tumors and encompass peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and several other entities of T-cell lymphoma.
A genetic analysis suggests that a rare blood cancer that affects immune T cells may be caused by exposure to smoking and aging-related mutations acquired during the early stage of production of new blood cells Mutations in blood cells likely caused by smoking and aging-related changes may lead to a rare type of blood cancer that affects immune cells.
Clinical Medical Laboratorians at Weill Cornell Medicine (New York, NY, USA) used next-generation genome sequencing to analyze 537 genes in 27 patients with AITL or PTCL for genetic changes that might lead to these T-cell tumors and to secondary cancers in some patients. All tissue samples (27 lymph node [LN] tissue specimens, 27 bone marrow [BM] aspirate/peripheral blood [PB] samples) were collected from 25 AITL or two PTCL NOS patients who were diagnosed or confirmed from June 2010 to December 2019.
The tumor burden estimate was also based on more objective and sensitive immunophenotypic findings by flow cytometry). A 537-gene targeted sequencing panel, based on hybridization capture method for sequencing library construction and selection, was designed to investigate the genomic profile of the primary tumors and the BM/PB tissues. The NGS libraries were constructed using the KAPA Hyperplus Kit (Roche, Basel, Switzerland), and hybrid selection was performed with the probes from the customized Twist Library Prep Kit (Twist Biosciences, San Francisco, CA, USA). Multiplexed libraries were sequenced using 150 bp paired end HiSeq 4000 sequencers (Illumina, San Diego, CA, USA). Targeted enrichment of 45 genes recurrently mutated in myeloid malignancies was performed using the Thunderstorm system with a customized primer panel.
The scientists reported that in about 70% of the patients, there were mutations in precursor cells, most likely stem cells, in the bone marrow that can lead to the production of growing numbers of blood cells with these mutations, as well as early development of the T-cell tumors. These mutations in the precursor cells have been thought to be related to aging. In addition, the team found that the mutations associated with the progression of these tumors might be linked to smoking or exposure to second-hand smoke. They also found that patients with a higher mutation burden of one of the genes associated with the early development of these tumors were at higher risk of developing additional types of tumors.
Wayne Tam, MD, PhD, a Professor of Pathology and Laboratory Medicine and senior author of the study, said, “Our results provide new information on how exposure to smoking may cooperate with early mutations in blood precursor cells to lead to the development of certain T-cell cancers. The findings suggest a potential new way to identify patients with AITL or PTCL who are most at risk of developing secondary tumors, and may also help scientists and clinicians improve how these cancers are prevented, diagnosed and treated.”
The authors concluded that they provided genetic evidence that AITL/PTCL-NOS, clonal hematopoiesis (CH), and concomitant hematologic neoplasms (CHN) can frequently arise from common mutated hematopoietic precursor clones. The study also suggests smoking exposure as a potential risk factor for AITL/PTCL-NOS progression. The study was published on September 28, 2021 in the journal eLife.
Related Links:
Weill Cornell Medicine
Roche
Twist Biosciences
Illumina
A genetic analysis suggests that a rare blood cancer that affects immune T cells may be caused by exposure to smoking and aging-related mutations acquired during the early stage of production of new blood cells Mutations in blood cells likely caused by smoking and aging-related changes may lead to a rare type of blood cancer that affects immune cells.
Clinical Medical Laboratorians at Weill Cornell Medicine (New York, NY, USA) used next-generation genome sequencing to analyze 537 genes in 27 patients with AITL or PTCL for genetic changes that might lead to these T-cell tumors and to secondary cancers in some patients. All tissue samples (27 lymph node [LN] tissue specimens, 27 bone marrow [BM] aspirate/peripheral blood [PB] samples) were collected from 25 AITL or two PTCL NOS patients who were diagnosed or confirmed from June 2010 to December 2019.
The tumor burden estimate was also based on more objective and sensitive immunophenotypic findings by flow cytometry). A 537-gene targeted sequencing panel, based on hybridization capture method for sequencing library construction and selection, was designed to investigate the genomic profile of the primary tumors and the BM/PB tissues. The NGS libraries were constructed using the KAPA Hyperplus Kit (Roche, Basel, Switzerland), and hybrid selection was performed with the probes from the customized Twist Library Prep Kit (Twist Biosciences, San Francisco, CA, USA). Multiplexed libraries were sequenced using 150 bp paired end HiSeq 4000 sequencers (Illumina, San Diego, CA, USA). Targeted enrichment of 45 genes recurrently mutated in myeloid malignancies was performed using the Thunderstorm system with a customized primer panel.
The scientists reported that in about 70% of the patients, there were mutations in precursor cells, most likely stem cells, in the bone marrow that can lead to the production of growing numbers of blood cells with these mutations, as well as early development of the T-cell tumors. These mutations in the precursor cells have been thought to be related to aging. In addition, the team found that the mutations associated with the progression of these tumors might be linked to smoking or exposure to second-hand smoke. They also found that patients with a higher mutation burden of one of the genes associated with the early development of these tumors were at higher risk of developing additional types of tumors.
Wayne Tam, MD, PhD, a Professor of Pathology and Laboratory Medicine and senior author of the study, said, “Our results provide new information on how exposure to smoking may cooperate with early mutations in blood precursor cells to lead to the development of certain T-cell cancers. The findings suggest a potential new way to identify patients with AITL or PTCL who are most at risk of developing secondary tumors, and may also help scientists and clinicians improve how these cancers are prevented, diagnosed and treated.”
The authors concluded that they provided genetic evidence that AITL/PTCL-NOS, clonal hematopoiesis (CH), and concomitant hematologic neoplasms (CHN) can frequently arise from common mutated hematopoietic precursor clones. The study also suggests smoking exposure as a potential risk factor for AITL/PTCL-NOS progression. The study was published on September 28, 2021 in the journal eLife.
Related Links:
Weill Cornell Medicine
Roche
Twist Biosciences
Illumina
Latest Hematology News
- Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
- Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
- Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
- Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
- Advanced CBC-Derived Indices Integrated into Hematology Platforms
- Blood Test Enables Early Detection of Multiple Myeloma Relapse
- Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
- Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
- Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
- New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
- Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
- AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
- Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
Channels
Clinical Chemistry
view channel
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
Simple Cytogenetic Method Could Improve Classification of ALL Subtypes
Many cancers deviate from the normal chromosome number, but the clinical impact of extreme chromosome loss remains unclear. This widespread genomic disruption is associated with aggressive disease and... Read more
Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
Sarcomas remain difficult to monitor during immunotherapy, as low tumor mutation burden can limit traditional circulating tumor DNA approaches and repeat tissue biopsies are often impractical in advanced disease.... Read moreImmunology
view channel
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
FDA Approval Expands Automated PD-L1 Testing Across Solid Tumors
Clinical laboratories play a central role in guiding immunotherapy by reporting programmed death ligand-1 (PD‑L1) status across multiple solid tumors. Many sites are standardizing this work on fully automated... Read more
AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
Tertiary lymphoid structures are emerging as important indicators of antitumor immunity, but their heterogeneity and spatial context within tumors remain difficult to capture through routine diagnostics.... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel








